# US 10,245,310 B2 · Carrier molecule for antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,310 B2
- Document ID: US10245310B2
- Status: Granted
- Kind: B2
- Application number: 15/501,474
- Filed: 2015-08-05
- Published: 2017-08-10
- Granted: 2019-04-02
- Earliest claimed: 2014-08-05
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals SA
- Inventors: Francesco Berti; Roberta Cozzi; Domenico Maione; Cira Daniela Rinaudo; Immaculada Margarit Y Ros; Guido Grandi
- Web page: https://patentgrep.com/patent/US10245310B2

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/09: {Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus}, streptococcus
- A61K 39/095: Neisseria
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.

## Claims

### Claim 1

A conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises BP-2a polypeptides derived from different Streptococcus agalactiae strains and a Streptococcus agalactiae spb1 polypeptide as a single polypeptide chain, said polypeptide chain having an amino acid sequence at least 70% identity to SEQ ID NO:276.

### Claim 2 (depends on 1)

The conjugate according to claim 1, wherein the spb1 polypeptide comprises a sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:206; and
(b) a fragment of SEQ ID NO:206 comprising amino acids 185 to 468.

### Claim 3 (depends on 1)

The conjugate according to claim 1, wherein the carrier molecule comprises a BP-2a polypeptide having an amino acid sequence selected from the group consisting of
SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46.

### Claim 4 (depends on 1)

The conjugate according to claim 1, wherein said BP-2a polypeptides are separated by a linker amino acid sequence.

### Claim 5 (depends on 1)

The conjugate according to claim 1, wherein the antigen is a saccharide.

### Claim 6 (depends on 5)

The conjugate according to claim 5, wherein the saccharide is a capsular saccharide from Streptococcus agalactiae.

### Claim 7 (depends on 6)

The conjugate according to claim 6, wherein the saccharide is a capsular saccharide from Streptococcus agalactiae serotype II or V.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a conjugate according to claim 1 in combination with a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, comprising a mixture of conjugates comprising saccharides from at least two of Streptococcus agalactiae serotypes selected from the group consisting of types Ia, Ib, II, III and V.

### Claim 10 (depends on 1)

A method for raising an immune response in a mammal, comprising administering an immunologically effective amount of a conjugate according to claim 1 to the mammal.

### Claim 11

A conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises an amino acid sequence having SEQ ID NO:276.

### Claim 12 (depends on 8)

A method for raising an immune response in a mammal, comprising administering an immunologically effective amount of a pharmaceutical composition according to claim 8 to the mammal.

### Claim 13 (depends on 11)

The conjugate according to claim 11, wherein the antigen is a saccharide.

### Claim 14 (depends on 13)

The conjugate according to claim 13, wherein the saccharide is a capsular saccharide from Streptococcus agalactiae.

### Claim 15 (depends on 14)

The conjugate according to claim 14, wherein the saccharide is a capsular saccharide from Streptococcus agalactiae serotype II or V.

### Claim 16 (depends on 11)

A pharmaceutical composition comprising a conjugate according to claim 11 in combination with a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, comprising a mixture of conjugates comprising saccharides from at least two of Streptococcus agalactiae serotypes selected from the group consisting of types Ia, Ib, II, III and V.

### Claim 18 (depends on 11)

A method for raising an immune response in a mammal, comprising administering an immunologically effective amount of a conjugate according to claim 11 to the mammal.